Novartis sues Chinese firm over attempts to make generic heart failure drug
30-09-2021
Novartis and others in ‘unprecedented’ COVID-19 partnership
27-03-2020
Novartis tries to block generic versions of Gilenya, enforces new patent
30-01-2020
II.studio / Shutterstock.com
Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, UKIPO, Boston Healthcare, trademark opposition, Emolite, Edomige, emollient, healthcare, UK Intellectual Property Office
